NEW YORK (GenomeWeb News) – Qiagen and Clovis Oncology announced after the close of the market on Monday a partnership to develop a companion diagnostic for a candidate oncology drug being developed by Clovis.

The deal covers the co-development and co-commercialization of the test to guide the use of CO-1686 being developed by Clovis to initially target an unmet clinical need in patients with epidermal growth factor receptor-driven non-small cell lung cancer who no longer respond to EGFR-inhibiting drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.